Previous Close | 17.61 |
1-Year Change | -3.14% |
6-Months Change | 29.2% |
3-Months Change | -8.16% |
Moving Avg (50d) | 18.575 |
Moving Avg (200d) | 16.51 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 1.88B |
Beta (3-Years) | 1.45 |
Revenue Growth (ttm) | -7.12% |
Net Profit Margin (ttm) | -39.14% |
Return On Assets (ttm) | -17.21% |
EPS (ttm) | -1.86 |
PE Ratio (ttm) | -9.47 |
Dividend Yield | % |
Asset Description: | NovoCure Limited |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-11 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
17.258 | 16.73 | 16.377 | 15.849 | 14.969 | 14.088 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Health Care Supplies |
Country: | United States |